Latest filings (excl ownership)
S-3/A
Shelf registration (amended)
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
8-K
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
11 Apr 24
8-K
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
28 Mar 24
8-K
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
25 Mar 24
8-K
Other Events
7 Mar 24
8-K
Results of Operations and Financial Condition
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Lipocine to Present at 36th Annual Roth Conference
6 Mar 24
8-K
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
12 Feb 24
8-K
Lipocine and Verity Pharma Enter into License Agreement
18 Jan 24
8-K
Other Events
8 Jan 24
8-K
Lipocine to Present at Biotech Showcase 2024
19 Dec 23
S-3
Shelf registration
22 Nov 23
8-K
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
13 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Other Events
8 Nov 23
8-K
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
1 Nov 23
8-K
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
26 Oct 23
8-K
Other Events
23 Oct 23
8-K
Termination of a Material Definitive Agreement
6 Oct 23
8-K
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
19 Sep 23
8-K
Other Events
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Other Events
27 Jul 23
8-K
Other Events
26 Jun 23
8-K
Other Events
26 Jun 23
8-K
Other Events
23 Jun 23
8-K
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
14 Jun 23
8-K
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
7 Jun 23
8-K
Other Events
31 May 23
8-K
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine’s Oral Candidate for Rapid Relief of Depression
16 May 23
8-K
Material Modifications to Rights of Security Holders
11 May 23
8-K
Other Events
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Other Events
5 May 23
424B5
Prospectus supplement for primary offering
3 Apr 23
8-K
First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
3 Apr 23
DEF 14A
Definitive proxy
27 Mar 23
ARS
2022 FY
Annual report to shareholders
20 Mar 23
Latest ownership filings
4
Mahesh V. Patel
12 Mar 24
4
Krista Fogarty
12 Mar 24
4
Mahesh V. Patel
25 May 23
4
Spyros Papapetropoulos
12 May 23
4
John W. Higuchi
12 May 23
4
Richard Dana Ono
12 May 23
4
Jill M. Jene
12 May 23
4
Jeffrey Arvin Fink
12 May 23
4
Mahesh V. Patel
24 Mar 23
4
Richard Dana Ono
20 Mar 23
4
Mahesh V. Patel
17 Mar 23
4
Mahesh V. Patel
4 Jan 23
4
Mahesh V. Patel
22 Dec 22
4
Krista Fogarty
22 Dec 22
4
Spyros Papapetropoulos
28 Nov 22
4
Mahesh V. Patel
14 Nov 22
4
George Nomikos
8 Nov 22
3
George Nomikos
8 Nov 22
4
Mahesh V. Patel
27 Sep 22
4
Richard Dana Ono
10 Jun 22
4
John W. Higuchi
10 Jun 22
4
Spyros Papapetropoulos
10 Jun 22
4
Jeffrey Arvin Fink
10 Jun 22
4
Jill M. Jene
10 Jun 22
4
Krista Fogarty
17 May 22
4
Mahesh V. Patel
16 May 22
4
Spyros Papapetropoulos
12 Apr 22
3
Spyros Papapetropoulos
12 Apr 22
4
Jill M. Jene
12 Apr 22
3
Jill M. Jene
12 Apr 22
SC 13G/A
VANGUARD GROUP INC
10 Feb 22
3
Krista Fogarty
27 Jan 22
4
Mahesh V. Patel
3 Jan 22
4
Mahesh V. Patel
8 Dec 21
4
MORGAN R BROWN
8 Dec 21
4
Mahesh V. Patel
18 Nov 21
4
Richard Dana Ono
10 Jun 21
4
John W. Higuchi
10 Jun 21
4
Jeffrey Arvin Fink
10 Jun 21
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
11 Feb 21